Fluorouracil
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1962
- First approval year
- 1962
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Fluorouracil
- Molecular weight
- 130.08
- Structure (SMILES)
- O=c1[nH]cc(F)c(=O)[nH]1
- 5 f u
- 5.f.u.
- accusite
- Accusite
- actikerall
- Actikerall
- adrucil
- Adrucil
- carac
- Carac
- efudex
- Efudex
- efudix
- Efudix
- fluoro uracil roche
- Fluoro-uracil roche
- fluoroplex
- Fluoroplex
- fluorouracil
- Fluorouracil
- fluorouracil component of folfox
- Fluorouracil component of folfox
- tolak
- Tolak
- 5 - Fluorouracil
- 5 - FU
- 5 fluorouracil
- 5 Fluorouracil
- 5 Fluorouracil (5 FU) Cream
- 5 Fluorouracil (5FU)
- 5 Fluorouracil (FU)
- 5 Fluorouracil (systemic)
- 5 fluorouracil iarc
- 5 fluorouracil who ip
- 5 fluoruracil
- 5 fu
- 5 FU
- 5- fluorouracil
- 5- Fluorouracil
- 5- Fluorouracil (5-FU)
- 5- FU (5-Fluorouracil)
- 5-fluorouracil
- 5-Fluorouracil
- 5-FluoroUracil
- 5-FLUOROURACIL
- 5-fluorouracil ( in FOLFOX)
- 5-fluorouracil (5-FU)
- 5-Fluorouracil (5-FU)
- 5-FLUOROURACIL (5-FU)
And 112 more, listed on the interactive page.
- CAS registry numbers
- 51-21-8
- ChEMBL ID
- CHEMBL185
- InChIKey
- GHASVSINZRGABV-UHFFFAOYSA-N
- PubChem compound IDs
- 3385
- RxNorm IDs (RxCUI)
- 4492
- FDA ingredient codes (UNII)
- U3P01618RT
- L01BC02
- L01BC52
Sources for recorded values
- Applicant
- EXTROVIS
- Approval date
- 29 Jul 1970
- Application number
- NDA016831
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- 5-fluorouracil
- Type
- Synthetic organic
- Drug name stem
- -racil; -uracil
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- topical
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Mechanism
- RNA inhibitor
- Action type
- Inhibitor
- Target
- RNA
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
- Protein identifier
- P04818
Open Targets mechanisms
- Mechanism
- Thymidylate synthase inhibitor
- Action type
- Inhibitor
- Target
- Thymidylate synthase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TYMS
- Protein identifier
- P04818
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Adenocarcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Glioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000326
- Subject identifier
- D005910
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001075
- Subject identifier
- D010051
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Myeloproliferative Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002428
- Subject identifier
- D009196
- Condition
- Keratosis, Actinic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0002496
- Subject identifier
- D055623
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002916
- Subject identifier
- D004938
And 89 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000182
- Condition identifier
- EFO_0000228
- Condition identifier
- EFO_0000294
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000326
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000409
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000681
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002496
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002938
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003100
- Condition identifier
- EFO_0003859
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003863
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003891
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003897
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 3
And 216 more, listed on the interactive page.
- Event
- anaemia
- Reports
- 1,257
- Reporting signal score
- 444.169
- Event
- arteriospasm coronary
- Reports
- 553
- Reporting signal score
- 1,219.95
- Event
- bone marrow failure
- Reports
- 862
- Reporting signal score
- 913.207
- Event
- cardiotoxicity
- Reports
- 288
- Reporting signal score
- 484.804
- Event
- decreased appetite
- Reports
- 1,982
- Reporting signal score
- 892.26
- Event
- dehydration
- Reports
- 1,845
- Reporting signal score
- 991.797
- Event
- dermatitis acneiform
- Reports
- 272
- Reporting signal score
- 548.812
- Event
- diarrhoea
- Reports
- 8,039
- Reporting signal score
- 4,857.5
- Event
- disease progression
- Reports
- 2,994
- Reporting signal score
- 3,431.69
- Event
- febrile neutropenia
- Reports
- 1,859
- Reporting signal score
- 1,731.75
- Event
- gastrointestinal toxicity
- Reports
- 412
- Reporting signal score
- 804.063
- Event
- general physical health deterioration
- Reports
- 686
- Reporting signal score
- 479.109
- Event
- haematotoxicity
- Reports
- 289
- Reporting signal score
- 439.509
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 421.667
- Event
- leukopenia
- Reports
- 1,366
- Reporting signal score
- 1,080.07
- Event
- malignant neoplasm progression
- Reports
- 1,564
- Reporting signal score
- 1,424.29
- Event
- metastases to bone
- Reports
- 586
- Reporting signal score
- 829.07
- Event
- metastases to liver
- Reports
- 826
- Reporting signal score
- 1,444.15
- Event
- mucosal inflammation
- Reports
- 1,916
- Reporting signal score
- 3,192.49
- Event
- nausea
- Reports
- 5,281
- Reporting signal score
- 1,026.94
- Event
- neuropathy peripheral
- Reports
- 2,203
- Reporting signal score
- 1,914.42
- Event
- neurotoxicity
- Reports
- 836
- Reporting signal score
- 1,071.04
- Event
- neutropenia
- Reports
- 3,849
- Reporting signal score
- 3,490.61
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 3,195
- Reporting signal score
- 7,471.51
- Event
- skin toxicity
- Reports
- 466
- Reporting signal score
- 841.92
And 3 more, listed on the interactive page.
- NCT00000122
- NCT02767219
- NCT00000758
- NCT00001428
- NCT00065117
- NCT00143403
- NCT00385021
- NCT00609622
- NCT00615056
- NCT00813137
- NCT00839111
- NCT00889343
- NCT00973609
- NCT00988897
- NCT01289821
- NCT01765582
- NCT02124148
- NCT02244632
- NCT02246049
- NCT02384850
- NCT02842580
- NCT02885753
- NCT03050814
- NCT03487939
- NCT05081687
And 1,316 more, listed on the interactive page.
- Dose
- 400 mg/m2 then 2,400-3,000 mg/m2 over 46 hours
- Route
- Intravenous
- How often
- Once every two weeks
- Do not inject entire contents of vial directly into patient
- Use within 4 hours of puncture
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 65.72
- Calculated partition coefficient (ALogP)
- -0.8
- Calculated partition coefficient (XLogP)
- -0.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 9
- Molecular formula
- C4H3FN2O2
- Monoisotopic mass
- 130.01785550
- Natural product
- No
- 0187-3204
- 0378-4791
- 16714-178
- 16729-276
- 16729-542
- 21922-041
- 21922-049
- 25021-215
- 28105-421
- 46708-751
- 46708-779
- 51862-362
- 55150-496
- 55150-497
- 55150-498
- 55150-499
- 62332-751
- 62332-779
- 63323-117
- 68001-524
- 68001-525
- 68001-627
- 68001-628
- 68083-269
- 68083-270
And 16 more, listed on the interactive page.
- Recorded assays
- 47,637
- Active assays
- 17,561
- Confirmatory
- Other
- Screening
- Summary
- Antimetabolites
- Antimetabolites, Antineoplastic
- Immunosuppressive Agents
Distribution coefficient (LogD)
- Median
- -0.89
- Mean
- -0.89
- Minimum
- -0.89
- Maximum
- -0.89
- Unit
- unitless
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Liver toxicity assay
- Median
- 28,500
- Mean
- 47,333.3
- Minimum
- 28,500
- Maximum
- 85,000
- Unit
- nM
- Assays
- 3
- Standard deviation
- 32,620.3
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Oral bioavailability
- Median
- 49
- Mean
- 49
- Minimum
- 49
- Maximum
- 49
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (2,122)
- (TAP) Block vs. Systemic Lidocaine: Effects on Recovery
- [18F]FPIA PET/CT Imaging in Patients With Solid Tumours
- [F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
- 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
- 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
- 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
- 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
- 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
- 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
- 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
- 5-fluorouracil for Treatment of Stable Vitiligo
- 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
- 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
- 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Approved for (7)
- Actinic keratosis
- Adenocarcinoma
- Basal cell carcinoma
- Cancer
- Gastroesophageal junction adenocarcinoma
- Keratosis
- Neoplasm
In development for (108)
- Anal carcinoma Phase 3
- Anus cancer Phase 3
- Anus neoplasm Phase 3
- Bile duct cancer Phase 2
- Bile duct carcinoma Phase 2
- Biliary tract cancer Phase 3
- Biliary tract neoplasm Phase 3
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Carcinoma Phase 3
- Carcinoma of esophagus Phase 3
- Central nervous system cancer Phase 1
- Cervical cancer Phase 3
- Chalazion Phase 3
- Cholangiocarcinoma Phase 3
- Colon adenocarcinoma Phase 3
- Colon carcinoma Phase 3
- Colonic neoplasm Phase 3
- Colorectal adenocarcinoma Phase 3
- Colorectal cancer Phase 3
Other linked conditions (1)
- Plantar wart
Targets (1)
- TYMS Thymidylate synthase inhibitor